Loading RMD detail
Loading ticker data...
Loading RMD detail
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.
The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Chart data unavailable
Aaron Wealth Advisors LLC lessened its stake in shares of ResMed Inc. (NYSE: RMD) by 53.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,938 shares of the medical equipment provider's stock after selling 2,210 shares during the period. Aaron Wealth
Azzad Asset Management Inc. ADV lifted its position in shares of ResMed Inc. (NYSE: RMD) by 271.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,463 shares of the medical equipment provider's stock after buying an additional 3,261 shares during the quarter. Azzad Asset
Runnymede Capital Advisors Inc. acquired a new stake in shares of ResMed Inc. (NYSE: RMD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,837 shares of the medical equipment provider's stock, valued at approximately $1,165,000. Other institutional investors have
GraniteShares Advisors LLC lessened its position in ResMed Inc. (NYSE: RMD) by 90.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 241 shares of the medical equipment provider's stock after selling 2,336 shares during the quarter. GraniteShares Advisors LLC's holdings in
ResMed Inc. (NYSE: RMD - Get Free Report) Director Peter Farrell sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total transaction of $450,000.00. The transaction was disclosed in a filing with the Securities and Exchange Commission,
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. NVDA, RL, RMD and GE hold promise.
SG Americas Securities LLC decreased its holdings in ResMed Inc. (NYSE: RMD) by 17.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,074 shares of the medical equipment provider's stock after selling 10,027 shares during the quarter. SG Americas Securities
ResMed (RMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Danske Bank A S acquired a new stake in shares of ResMed Inc. (NYSE: RMD) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 161,546 shares of the medical equipment provider's stock, valued at approximately $44,220,000. Danske Bank A S
Achmea Investment Management B.V. lowered its holdings in ResMed Inc. (NYSE: RMD) by 41.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 138,375 shares of the medical equipment provider's stock after selling 99,277 shares during the quarter. Achmea Investment Management B.V. owned
ResMed (RMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RMD expands mask and device sales while maintaining strong liquidity, but macro and competitive pressures loom.
The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Aquatic Capital Management LLC raised its stake in ResMed Inc. (NYSE: RMD) by 106.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,564 shares of the medical equipment provider's stock after acquiring an additional 12,642 shares during the quarter. Aquatic
